Progress in Targeted Therapy of Low-Flow Vascular Malformation

doi:10.3969/j.issn.1673-0364.2020.03.008

Abstract

Abstract: With the introduction of the concept of precision medicine and the breakthrough in the genetics of vascular malformation, developing targeted therapies for low-flow vascular malformation has become a hot spot and urgent task of current research. Low-flow vascular malformation has been confirmed by the presence of somatic activation mutations leading to the continuous activation of the PI3K/AKT/ mTOR pathway, which indicates the possibility of targeted therapies. In this paper, the current researches and applications of targeted drugs in the treatment of low-flow vascular malformation were reviewed.

Key words: Venous malformation, Lymphatic malformation, Targeted therapy, Sirolimus

CLC Number:

R732.2

Hongyuan LIU, Tongxin GE, Xiaoxi LIN. Progress in Targeted Therapy of Low-Flow Vascular Malformation[J]. Journal of Tissue Engineering and Reconstructive Surgery, 2020, 16(3): 204-209.

References 75

[1]	International Society for the Study of Vascular Anomalies. ISSVA classification for Vascular Anomalies [EB/OL]. ( 2018- 06- 30)[2020-04-22]. .
[2]	中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019,15(5):277-317.
[3]	Dasgupta R, Patel M . Venous malformations[J]. Semin Pediatr Surg, 2014,23(4):198-202.
[4]	Soblet J, Limaye N, Uebelhoer M , et al. Variable somatic TIE2 mutations in half of sporadic venous malformations[J]. Mol Syndromol, 2013,4(4):179-183.
[5]	Limaye N, Wouters V, Uebelhoer M , et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations[J]. Nat Genet, 2009,41(1):118-124.
[6]	Vikkula M, Boon LM , Carraway KL 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2[J]. Cell, 1996,87(7):1181-1190.
[7]	Soblet J, Kangas J, Nätynki M , et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations[J]. J Invest Dermatol, 2017,137(1):207-216.
[8]	Limaye N, Kangas J, Mendola A , et al. Somatic activating PIK3CA mutations cause venous malformation[J]. Am J Hum Genet, 2015,97(6):914-921.
[9]	Castel P, Carmona FJ, Grego-Bessa J , et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations[J]. Sci Transl Med, 2016, 8(332):332ra42.
[10]	Li X, Cai Y, Goines J , et al. Ponatinib combined with rapamycin causes regression of murine venous malformation[J]. Arterioscler Thromb Vasc Biol, 2019,39(3):496-512.
[11]	Boscolo E, Limaye N, Huang L , et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects[J]. J Clin Invest, 2015,125(9):3491-3504.
[12]	Castillo SD, Tzouanacou E, Zaw-Thin M , et al. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans[J]. Sci Transl Med, 2016, 8(332):332ra43.
[13]	Tammela T, Alitalo K . Lymphangiogenesis: Molecular mechanisms and future promise[J]. Cell, 2010,140(4):460-476.
[14]	Luks VL, Kamitaki N, Vivero MP , et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA[J]. J Pediatr, 2015,166(4):1048-1054.
[15]	Osborn AJ, Dickie P, Neilson DE , et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations[J]. Hum Mol Genet, 2015,24(4):926-938.
[16]	Boscolo E, Coma S, Luks VL , et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation[J]. Angiogenesis, 2015,18(2):151-162.
[17]	Blesinger H, Kaulfuß S, Aung T , et al. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations[J]. PLoS One, 2018,13(7):e0200343.
[18]	Trenor CC 3rd, Chaudry G . Complex lymphatic anomalies[J]. Semin Pediatr Surg, 2014,23(4):186-190.
[19]	Ozeki M, Fukao T . Generalized lymphatic anomaly and gorham-stout disease: overview and recent insights[J]. Adv Wound Care (New Rochelle), 2019,8(6):230-245.
[20]	Hagendoorn J, Yock TI, Borel Rinkes IH , et al. Novel molecular pathways in Gorham disease: implications for treatment[J]. Pediatr Blood Cancer, 2014,61(3):401-406.
[21]	Croteau SE, Kozakewich HP, Perez-Atayde AR , et al. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly[J]. J Pediatr, 2014,164(2):383-388.
[22]	Dellinger MT, Garg N, Olsen BR . Viewpoints on vessels and vanishing bones in Gorham-Stout disease[J]. Bone, 2014,63:47-52.
[23]	Barclay SF, Inman KW, Luks VL , et al. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis[J]. Genet Med, 2019,21(7):1517-1524.
[24]	Boscolo E, Pastura P, Glaser K , et al. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis[J]. Pediatr Blood Cancer, 2019,66(8):e27790.
[25]	Rodriguez-Laguna L, Agra N, Ibañez K , et al. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly[J]. J Exp Med, 2019,216(2):407-418.
[26]	Manevitz-Mendelson E, Leichner GS, Barel O , et al. Somatic NRAS mutation in patient with generalized lymphatic anomaly[J]. Angiogenesis, 2018,21(2):287-298.
[27]	Li D, Wenger TL, Seiler C , et al. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly[J]. Hum Mol Genet, 2018,27(18):3233-3245.
[28]	Keppler-Noreuil KM, Rios JJ, Parker VE , et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation[J]. Am J Med Genet A, 2015,167A(2):287-295.
[29]	Parker VER, Keppler-Noreuil KM, Faivre L , et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum[J]. Genet Med, 2019,21(5):1189-1198.
[30]	Venot Q, Blanc T, Rabia SH , et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome[J]. Nature, 2018,558(7711):540-546.
[31]	Gits CC, Nelson SC, Feltis BA , et al. Multimodal therapy in the treatment of a venolymphatic malformation of the axilla and chest wall in an infant[J]. J Vasc Surg Venous Lymphat Disord, 2014,2(4):451-454.
[32]	Kim D, Benjamin L, Wysong A , et al. Treatment of complex periorbital venolymphatic malformation in a neonate with a combina-tion therapy of sirolimus and prednisolone[J]. Dermatol Ther, 2015,28(4):218-221.
[33]	Goldenberg DC, Carvas M, Adams D , et al. Successful treatment of a complex vascular malformation with sirolimus and surgical resection[J]. J Pediatr Hematol Oncol, 2017,39(4):e191-e195.
[34]	Hammer J, Seront E, Duez S , et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study[J]. Orphanet J Rare Dis, 2018,13(1):191.
[35]	Mack JM, Verkamp B, Richter GT , et al. Effect of sirolimus on coagulopathy of slow-flow vascular malformations[J]. Pediatr Blood Cancer, 2019,66(10):e27896.
[36]	Seront E, Van Damme A, Boon LM , et al. Rapamycin and treatment of venous malformations[J]. Curr Opin Hematol, 2019,26(3):185-192.
[37]	Isoldi S, Belsha D, Yeop I , et al. Diagnosis and management of children with Blue Rubber Bleb Nevus Syndrome: A multi-center case series[J]. Dig Liver Dis, 2019,51(11):1537-1546.
[38]	Yuksekkaya H, Ozbek O, Keser M , et al. Blue rubber bleb nevus syndrome: successful treatment with sirolimus[J]. Pediatrics, 2012,129(4):e1080-e1084.
[39]	Salloum R, Fox CE, Alvarez-Allende CR , et al. Response of blue rubber bleb nevus syndrome to sirolimus treatment[J]. Pediatr Blood Cancer, 2016,63(11):1911-1914.
[40]	Zhang B, Li L, Zhang N , et al. Efficacy and safety of sirolimus in the treatment of blue rubber bleb naevus syndrome in paediatric patients[J]. Clin Exp Dermatol, 2020,45(1):79-85.
[41]	Wong XL, Phan K, Rodríguez Bandera AI , et al. Sirolimus in blue rubber bleb naevus syndrome: A systematic review[J]. J Paediatr Child Health, 2019,55(2):152-155.
[42]	Couto JA, Vivero MP, Kozakewich HPW , et al. A somatic MAP3K3 mutation is associated with verrucous venous malformation[J]. Am J Hum Genet, 2015,96(3):480-486.
[43]	Zhang G, Chen H, Zhen Z , et al. Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study[J]. J Am Acad Dermatol, 2019,80(2):556-558.
[44]	Cai R, Yang X, Gu H , et al. Sirolimus for the treatment of “verrucous” venous malformation: are we missing the lymphatic malformation component [J]? J Am Acad Dermatol, 2018: S0190- 9622(18) 32578-7.
[45]	Rössler J, Geiger J, Földi E , et al. Sirolimus is highly effective for lymph leakage in microcystic lymphatic malformations with skin involvement[J]. Int J Dermatol, 2017,56(4):e72-e75.
[46]	Lagrèze WA, Joachimsen L, Gross N , et al. Sirolimus-induced regression of a large orbital lymphangioma[J]. Orbit, 2019,38(1):79-80.
[47]	Ghariani Fetoui N, Boussofara L, Gammoudi R , et al. Efficacy of sirolimus in the treatment of microcystic lymphatic malformation of the tongue[J]. J Eur Acad Dermatol Venereol, 2019,33(9):e336-e337.
[48]	Triana P, Miguel M, Díaz M , et al. Oral sirolimus: an option in the management of neonates with life-threatening upper airway lymphatic malformations[J]. Lymphat Res Biol, 2019,17(5):504-511.
[49]	Alemi AS, Rosbe KW, Chan DK , et al. Airway response to sirolimus therapy for the treatment of complex pediatric lymphatic malformations[J]. Int J Pediatr Otorhinolaryngol, 2015,79(12):2466-2469.
[50]	Strychowsky JE, Rahbar R , O'Hare MJ, et al. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation[J]. Laryngoscope, 2018,128(1):269-276.
[51]	Tian R, Liang Y, Zhang W , et al. Effectiveness of sirolimus in the treatment of complex lymphatic malformations: Single center report of 56 cases[J]. J Pediatr Surg, 2020,[Epub ahead of print].
[52]	Ozeki M, Nozawa A, Yasue S , et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies[J]. Orphanet J Rare Dis, 2019,14(1):141.
[53]	Le Sage S, David M, Dubois J , et al. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series[J]. Pediatr Dermatol, 2018,35(4):472-477.
[54]	García-Montero P, Del Boz J, Baselga-Torres E , et al. Use of topical rapamycin in the treatment of superficial lymphatic malformations[J]. J Am Acad Dermatol, 2019,80(2):508-515.
[55]	Freixo C, Ferreira V, Martins J , et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review[J]. J Vasc Surg, 2020,71(1):318-327.
[56]	Ricci KW, Hammill AM, Mobberley-Schuman P , et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease[J]. Pediatr Blood Cancer, 2019,66(5):e27614.
[57]	Wang Z, Li K, Yao W , et al. Successful treatment of kaposiform lymphangiomatosis with sirolimus[J]. Pediatr Blood Cancer, 2015,62(7):1291-1293.
[58]	Adams DM , Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J]. Pediatrics, 2016,137(2):e20153257.
[59]	Mori M, Dictor M, Brodszki N , et al. Pulmonary and pleural lymphatic endothelial cells from pediatric, but not adult, patients with Gorham-Stout disease and generalized lymphatic anomaly, show a high proliferation rate[J]. Orphanet J Rare Dis, 2016,11(1):67.
[60]	Adams DM, Ricci KW . Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options[J]. Hematol Oncol Clin North Am, 2019,33(3):455-470.
[61]	Yesil S, Tanyildiz HG, Bozkurt C , et al. Single-center experience with sirolimus therapy for vascular malformations[J]. Pediatr Hematol Oncol, 2016,33(3):219-225.
[62]	Dodds M, Tollefson M, Castelo-Soccio L , et al. Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series[J]. Pediatr Dermatol, 2020,37(2):272-277.
[63]	Badia P, Ricci K, Gurria JP , et al. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series[J]. Pediatr Blood Cancer, 2020,67(4):e28088.
[64]	Vlahovic AM, Vlahovic NS, Haxhija EQ . Sirolimus for the treatment of a massive capillary-lymphatico-venous malformation: a case report[J]. Pediatrics, 2015,136(2):e513-e516.
[65]	Bessis D, Vernhet H, Bigorre M , et al. Life-threatening cutaneous bleeding in childhood klippel-trenaunay syndrome treated with oral sirolimus[J]. JAMA Dermatol, 2016,152(9):1058-1059.
[66]	González-Hermosa MR, Guerra E, Tuduri I , et al. CLAPO syndrome: Effective response to treatment with oral rapamycin[J]. Dermatol Ther, 2019,32(4):e12991.
[67]	Lee RA, Gabardi S . Current trends in immunosuppressive therapies for renal transplant recipients[J]. Am J Health Syst Pharm, 2012,69(22):1961-1975.
[68]	Nadal M, Giraudeau B, Tavernier E , et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review[J]. Acta Derm Venereol, 2016,96(4):448-452.
[69]	Wiegand S, Wichmann G, Dietz A . Treatment of lymphatic malformations with the mTOR inhibitor sirolimus: a systematic review[J]. Lymphat Res Biol, 2018,16(4):330-339.
[70]	Ying H, Qiao C, Yang X , et al. A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendo the liomas[J]. Pediatrics, 2018,141(Suppl 5):S425-S429.
[71]	Morath C, Arns W, Schwenger V , et al. Sirolimus in renal transplantation[J]. Nephrol Dial Transplant, , 2007,22(Suppl 8):viii61-viii65.
[72]	EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients[J]. Nephrol Dial Transplant, 2002,17 Suppl 4: 50-55.
[73]	Zuber J, Anglicheau D, Elie C , et al. Sirolimus may reduce fertility in male renal transplant recipients[J]. Am J Transplant, 2008,8(7):1471-1479.
[74]	González D, García CD, Azócar M , et al. Growth of kidney-transplanted pediatric patients treated with sirolimus[J]. Pediatr Nephrol, 2011,26(6):961-966.
[75]	López Gutiérrez JC, Lizarraga R, Delgado C , et al. Alpelisib treatment for genital vascular malformation in a patient with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal/skeletal anomalies and/or scoliosis (CLOVES) syndrome[J]. J Pediatr Adolesc Gynecol, 2019,32(6):648-650.